Nader Moaven, MD
Infectious Disease · Belleville, NJNPI 1831293174
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,934 of the $14,883 with a category attached, or 66.7%. Gilead accounts for 83.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $8,554 and has fallen 98.7% since, to $107 in 2023. Among infectious disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $66.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12K
- GSK$493
- Viiv Healthcare Company$412
- Amarin Pharma, Inc.$248
- Merck$200
- Globus Medical$199
- plus $949 from 16 others
What the payments were for
- Speaking & faculty fees$9,93467%
- Travel & lodging$1,2538%
- Food & beverage$3,68425%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 71 | $12,384 |
| GSK | 39 | $493 |
| Viiv Healthcare Company | 31 | $412 |
| Amarin Pharma, Inc. | 13 | $248 |
| Merck | 14 | $200 |
| Globus Medical | 1 | $199 |
| Novo Nordisk | 8 | $179 |
| Amgen(2 entities) | 10 | $134 |
| Medtronic(2 entities) | 2 | $133 |
| AbbVie(2 entities) | 8 | $115 |
| AstraZeneca | 6 | $89 |
| Pfizer | 4 | $48 |
| Napo Pharmaceuticals Inc | 3 | $44 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Abbott | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Seqirus USA Inc | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Descovy$11,510
- XLIF$199
- TRELEGY ELLIPTA$125
- ClosureFast$118
How this compares
$14,883 in reported general payments places this provider in the 90th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 131 | $582,411 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 22 | $87,419 |
| DovatoDolutegravir Sodium/Lamivudine | 18 | $74,270 |
| OzempicSemaglutide | 50 | $72,103 |
| EliquisApixaban | 64 | $67,169 |
| IsentressRaltegravir Potassium | 27 | $60,295 |
| JanuviaSitagliptin Phosphate | 44 | $57,989 |
| JardianceEmpagliflozin | 37 | $43,459 |
| VascepaIcosapent Ethyl | 66 | $37,861 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $37,559 |
| FarxigaDapagliflozin Propanediol | 22 | $33,923 |
| TradjentaLinagliptin | 18 | $26,376 |
| TrulicityDulaglutide | 18 | $22,499 |
| EntrestoSacubitril/Valsartan | 22 | $20,176 |
| XareltoRivaroxaban | 13 | $19,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $12,384 | $582,411131 claims |
| Viiv Healthcare CompanyTriumeq, Dovato | $412 | $161,68940 claims |
| MerckIsentress, Januvia, Janumet | $200 | $133,65682 claims |
| Novo NordiskOzempic | $179 | $72,10350 claims |
| PfizerEliquis, Abrysvo | $48 | $70,62776 claims |
| Boehringer IngelheimJardiance, Tradjenta | $14 | $69,83555 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix | $493 | $60,573134 claims |
| AstraZenecaFarxiga, Symbicort | $89 | $37,56636 claims |
| Lilly USA, LLCTrulicity | $25 | $22,49918 claims |
| Johnson & JohnsonXarelto | $14 | $19,52113 claims |
| AbbVieLinzess | $115 | $13,17823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Belleville
- Donald BeggsBelleville$13K
- Keith GottesdienerRahway$2.1M
- Jihad SlimNewark$2.1M
- Maria SzabelaNewark$474K
- Ronald NahassHillsborough$213K
- Christopher LucastiSomers Point$112K
- Spartaco BellomoJersey City$111K
- Jack BoghossianBayonne$97K
- Adriana GrigoriuJersey City$89K
- Sukrut DwivediOakhurst$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.